Dipexium Pharmaceut (DPRX) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dipexium Pharmaceuticals Reports Third Quarter 2015 Financial Results
November 16, 2015 7:00 AM ESTNEW YORK, Nov. 16, 2015 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended September 30, 2015.Â
"Our OneStep Phase 3, placebo-controlled, pivotal clinical trials of Locilex in the treatment of patients with mild infections of diabetic foot ulcers are approximately 62% enrolled," said David P. Luci, President and CEO of Dipexium Pharmaceuticals, "Based on the current pace of enrollment, we expect to complete enrollment in early... More
